Form 4: Adaptimmune Therapeutics PLC: Officer Acquires Options to Purchase Ordinary Shares

William C. Bertrand Jr., Chief Operating Officer of Adaptimmune Therapeutics PLC, acquired options to purchase ordinary shares in the company on February 20, 2025.

Summary

• On February 20, 2025, William C. Bertrand Jr., the Chief Operating Officer of Adaptimmune Therapeutics PLC, filed a Form 4 indicating changes in beneficial ownership.
• Bertrand acquired options to purchase 1,612,032 ordinary shares with an exercise price of $0.1, converted from GBP0.08, expiring on February 20, 2035.
• These options vest in installments starting February 20, 2026, with monthly installments thereafter.
• He also acquired options to purchase 1,074,696 ordinary shares with an exercise price of $0.0013, converted from GBP0.001, expiring on March 15 of each year following the year in which the installment becomes exercisable.
• These options vest in installments starting February 20, 2026, with annual installments thereafter.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports the grant of stock options, which is a common practice. It doesn't inherently indicate positive or negative performance, but rather aligns management incentives.

Positives

• The acquisition of options by a key officer could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the options suggest a multi-year commitment from the COO.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Comparison to Industry Standards

• Option grants are a standard component of executive compensation packages in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedules and exercise prices appear typical for such grants, designed to incentivize long-term value creation.

Stakeholder Impact

• The option grants could potentially incentivize the COO to improve company performance, benefiting shareholders.

Key Dates

Keywords

Adaptimmune Therapeutics, William Bertrand, options, ordinary shares, Form 4, beneficial ownership, COO, acquisition